About: Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2011 (uk) article scientifique publié en 2011 (fr) im Mai 2011 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q59231320-734B5C63-CB9B-42DC-9A77-E1ACBBFD3399
publication date	2011-05-23 00:00:00Z (xsd:dateTime)
author name string	wds:Q59231320-155250B5-F805-43E3-8CEC-F68CFB560321 wds:Q59231320-36D4EF12-6C54-4627-9896-46D0D32B2796 wds:Q59231320-4E5410F7-A387-440D-B406-9652BD1AB7D7 wds:Q59231320-934A94AF-16E6-4422-ADFC-BE743FA0DF13 wds:Q59231320-99883F1B-71A9-4C8F-813A-194B612C7434 wds:Q59231320-9B844684-FAD6-4003-9E21-26F4B4E13A27 wds:Q59231320-A7AFE9FB-C80F-40CC-80A4-4AFB3D553C2E wds:Q59231320-A88B8E02-944D-4252-8FE0-539B06EE1C1D wds:Q59231320-E8E0010C-7385-468A-AB55-5C0647662A8B wds:Q59231320-F4C41B00-E52B-459D-870B-9BA251C40911 wds:Q59231320-F54736FB-F8EB-4E35-A359-1A6A182797E6 wds:Q59231320-F6825915-D5BD-40CC-B07E-5FC01085D1CC wds:Q59231320-FF56D5C7-765C-4F53-9958-67041E05A5AC
author name string	Lorenza Landi Enzo Maria Ruggeri Giovanni Lo Re Mimma Rizzo Emilio Bajetta Chiara Paglino Fable Zustovich Ilaria Imarisio Isabella Chiappino Riccardo Ricotta Roberto Sabbatini Valentina Guadalupi Anna Calcagno
rdfs:label	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (en) Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (nl)
skos:prefLabel	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (en) Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (nl)
name	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (en) Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (nl)
author	wds:Q59231320-26C09D15-26F1-4E2E-9C0D-B08AD6F29228 wds:Q59231320-37F1C68E-2ED7-48E3-8914-E9EBDC0B041E wds:Q59231320-4FA51A62-CF36-41B8-ABD4-AEB49328CB81 wds:Q59231320-AB4858D4-715F-4F2E-B3E4-A74C742EBCFE wds:Q59231320-D4264454-FC8C-4959-8E2D-562970A0E9FC
author	Camillo Porta Elena Verzoni Giuseppe Procopio Giacomo Cartenì Alessandra Bearz
title	wds:Q59231320-A08D92A7-2028-455A-B32D-9516E8B03626
title	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (en)
page(s)	wds:Q59231320-79D3BF90-3FF3-4389-B946-4FC0276BFE83
page(s)	E250-7
instance of	wds:Q59231320-4335CFA3-1291-46EE-A891-81EA45C8B7CC
instance of	scholarly article
main subject	wds:Q59231320-26A72EE3-FE7B-46F4-B872-66A9E56000A6
main subject	Patients
PubMed ID	wds:Q59231320-DA388D9E-965D-459F-B515-456760A02575
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21599821
PubMed ID	21599821
published in	wds:Q59231320-C142644A-B51A-45D2-8C6B-06523CE17E17
published in	BJU International
issue	wds:Q59231320-9CB0BBF0-D988-4134-8FF3-BF11EB90A0F0
volume	wds:Q59231320-EF6C4ADA-6DFF-46EA-9523-F16CADEDCC94
issue	8 Pt 2
volume	108
DOI	wds:Q59231320-74E74305-17DD-4B56-937B-710BFF15D9F5
DOI	http://dx.doi.org/10.1111/J.1464-410X.2011.10186.X
DOI	10.1111/J.1464-410X.2011.10186.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59231320
is cites work of	Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Protein kinase inhibitors in renal cell carcinoma. Treatment selection in metastatic renal cell carcinoma: expert consensus Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Sunitinib re-challenge in advanced renal-cell carcinoma Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Sunitinib in the treatment of metastatic renal cell carcinoma Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software